Nonsense Suppression as an Approach to Treat Lysosomal Storage Diseases
Open Access
Abstract
In-frame premature termination codons (PTCs) (also referred to as nonsense mutations) comprise ~10% of all disease-associated gene lesions. PTCs reduce gene expression in two ways. First, PTCs prematurely terminate translation of an mRNA, leading to the production of a truncated polypeptide that often lacks normal function and/or is unstable. Second, PTCs trigger degradation of an mRNA by activating nonsense-mediated mRNA decay (NMD), a cellular pathway that recognizes and degrades mRNAs containing a PTC. Thus, translation termination and NMD are putative therapeutic targets for the development of treatments for genetic diseases caused by PTCs. Over the past decade, significant progress has been made in the identification of compounds with the ability to suppress translation termination of PTCs (also referred to as readthrough). More recently, NMD inhibitors have also been explored as a way to enhance the efficiency of PTC suppression. Due to their relatively low threshold for correction, lysosomal storage diseases are a particularly relevant group of diseases to investigate the feasibility of nonsense suppression as a therapeutic approach. In this review, the current status of PTC suppression and NMD inhibition as potential treatments for lysosomal storage diseases will be discussed.Keywords
Funding Information
- National Institutes of Health (1R21OD19922-01A1)
- Cystic Fibrosis Foundation (KEELIN15XX0)
- Alabama Drug Discovery Alliance
- University of Pennsylvania Orphan Disease Center
This publication has 171 references indexed in Scilit:
- The 6‐minute walk test and other clinical endpoints in duchenne muscular dystrophy: Reliability, concurrent validity, and minimal clinically important differences from a multicenter studyMuscle & Nerve, 2013
- Attenuation of Nonsense-Mediated mRNA Decay Enhances In Vivo Nonsense SuppressionPLOS ONE, 2013
- A comparative evaluation of NB30, NB54 and PTC124 in translational read‐through efficacy for treatment of an USH1C nonsense mutationEMBO Molecular Medicine, 2012
- Pharmacological read‐through of nonsense ARSB mutations as a potential therapeutic approach for mucopolysaccharidosis VIJournal of Inherited Metabolic Disease, 2012
- Nonsense-mediated mRNA decay (NMD) in animal embryogenesis: to die or not to die, that is the questionCurrent Opinion in Genetics & Development, 2011
- Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54Journal of Molecular Medicine, 2011
- Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse modelJournal of Molecular Medicine, 2010
- Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type IMolecular Genetics and Metabolism, 2010
- Characterization of an MPS I-H knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutationMolecular Genetics and Metabolism, 2010
- The Role of ABCE1 in Eukaryotic Posttermination Ribosomal RecyclingMolecular Cell, 2010